Inhibitory Effect of Immunologically Activated Mesenchymal Stem Cells on Lung Cancer Cell Growth and Metastasis

Ye, Hong; Pan, Jiongwei; Gong, Enhui; Cai, Xiaoping; Xu, Cunlai; Li, Yuling; Zheng, Hao; Cao, Zhuo

doi:10.1089/cbr.2020.3855

Cited by 4 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, TLR7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid-derived suppressor cells in NSCLC [68]. A preclinical study showed that TLR7 agonists inhibit the growth and metastasis of lung cancer cells through immune activated mesenchymal stem cells [69]. Another study showed that R848-based stimulation of APCs in the tumor microenvironment resulted in the mobilization of an antitumor CD8 + immune response for treating metastatic NSCLC [70].…”

Section: Non-small Cell Lung Cancer (Nsclc)mentioning

confidence: 99%

Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives

Sun

Zhang

et al. 2022

Biomark Res

View full text Add to dashboard Cite

Toll-like receptors (TLRs) are a large family of proteins that are expressed in immune cells and various tumor cells. TLR7/8 are located in the intracellular endosomes, participate in tumor immune surveillance and play different roles in tumor growth. Activation of TLRs 7 and 8 triggers induction of a Th1 type innate immune response in the highly sophisticated process of innate immunity signaling with the recent research advances involving the small molecule activation of TLR 7 and 8. The wide range of expression and clinical significance of TLR7/TLR8 in different kinds of cancers have been extensively explored. TLR7/TLR8 can be used as novel diagnostic biomarkers, progression and prognostic indicators, and immunotherapeutic targets for various tumors. Although the mechanism of action of TLR7/8 in cancer immunotherapy is still incomplete, TLRs on T cells are involved in the regulation of T cell function and serve as co-stimulatory molecules and activate T cell immunity. TLR agonists can activate T cell-mediated antitumor responses with both innate and adaptive immune responses to improve tumor therapy. Recently, novel drugs of TLR7 or TLR8 agonists with different scaffolds have been developed. These agonists lead to the induction of certain cytokines and chemokines that can be applied to the treatment of some diseases and can be used as good adjutants for vaccines. Furthermore, TLR7/8 agonists as potential therapeutics for tumor-targeted immunotherapy have been developed. In this review, we summarize the recent advances in the development of immunotherapy strategies targeting TLR7/8 in patients with various cancers and chronic hepatitis B.

show abstract

Section: Non-small Cell Lung Cancer (Nsclc)mentioning

confidence: 99%

Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives

Sun

Zhang

et al. 2022

Biomark Res

View full text Add to dashboard Cite

show abstract

“…In addition to promoting tumor growth, MSCs also have tumor suppressive properties ( Ye et al, 2021 ). MSCs can suppress the proliferation of Kaposi’s sarcoma cells by inhibiting the activation of Akt signaling cascade ( Khakoo et al, 2006 ), which is involved in the proliferation and survival of cancer cells ( Madhunapantula et al, 2011 ).…”

Section: Mesenchymal Stem Cells (Mscs)mentioning

confidence: 99%

“…Wu et al (Wu et al, 2020) identified a panel of eight exosomal miRNAs that can effectively detect stage I or II lung cancer with high accuracy. Li et al (Li X. et al, 2021) found that miR3913-5p levels were associated with increased treatment resistance. The levels of miR-125b-5p and miR-5684 have diagnostic and prognostic values in lung cancer (Zhang Z. et al, 2020), while the level of miR-620 levels is significantly lower in patients with lung cancer (Tang et al, 2020).…”

Section: Regulatory Mechanisms Of Mscsderived Exosome In Cancermentioning

confidence: 99%

The role of mesenchymal stem cells derived exosomes as a novel nanobiotechnology target in the diagnosis and treatment of cancer

Zhou,

Dong,

Zhang

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs), one of the most common types of stem cells, are involved in the modulation of the tumor microenvironment (TME). With the advancement of nanotechnology, exosomes, especially exosomes secreted by MSCs, have been found to play an important role in the initiation and development of tumors. In recent years, nanobiotechnology and bioengineering technology have been gradually developed to detect and identify exosomes for diagnosis and modify exosomes for tumor treatment. Several novel therapeutic strategies bioengineer exosomes to carry drugs, proteins, and RNAs, and further deliver their encapsulated cargoes to cancer cells through the properties of exosomes. The unique properties of exosomes in cancer treatment include targeting, low immunogenicity, flexibility in modification, and high biological barrier permeability. Nevertheless, the current comprehensive understanding of the roles of MSCs and their secreted exosomes in cancer development remain inadequate. It is necessary to better understand/update the mechanism of action of MSCs-secreted exosomes in cancer development, providing insights for better modification of exosomes through bioengineering technology and nanobiotechnology. Therefore, this review focuses on the role of MSCs-secreted exosomes and bioengineered exosomes in the development, progression, diagnosis, and treatment of cancer.

show abstract

“…Umbilical cord MSCs (UCMSCs) are known to facilitate the proliferation and movement of lung cancer cells through the ERK–phospho-c-Fos-S374 pathway and to induce malignant characteristics of cancer cells through the AMPK signaling pathway ( 49 , 50 ). UCMSCs inhibit the growth and metastasis and promote the apoptosis of lung cancer cells by regulating the PI3K–Akt and NF-κB pathways ( 51 ). UCMSCs inhibit the proliferation, migration and invasion of glioblastoma cells by regulating the IL-6–JAK2–STAT3 signaling pathway, and promote the apoptosis of glioblastoma cells ( 52 ).…”

Section: Regulatory Effects Of Mscs From Different Sources On Tumor C...mentioning

confidence: 99%

Mesenchymal stem/stromal cells- a principal element for tumour microenvironment heterogeneity

Sun,

Yao

2023

Front. Immunol.

View full text Add to dashboard Cite

The heterogeneity of the tumor microenvironment (TME) is a major obstacle in cancer treatment, making most therapeutic interventions palliative rather than curative. Previous studies have suggested that the reason for the low efficacy of immunotherapy and the relapse of the original responders over time may be due to the complex network of mesenchymal stem/stromal cells (MSCs), a population of multipotent progenitor cells existing in a variety of tissues. Cancer-associated MSCs (CA-MSCs) have already been isolated from various types of tumors and are characterized by their vigorous pro-tumorigenic functions. Although the roles of CA-MSCs from different sources vary widely, their origins are still poorly understood. Current evidence suggests that when local resident or distally recruited MSCs interact with tumor cells and other components in the TME, “naïve” MSCs undergo genetic and functional changes to form CA-MSCs. In this review, we mainly focus on the multiple roles of CA-MSCs derived from different sources, which may help in elucidating the formation and function of the entire TME, as well as discover innovative targets for anti-cancer therapies.

show abstract

Inhibitory Effect of Immunologically Activated Mesenchymal Stem Cells on Lung Cancer Cell Growth and Metastasis

Cited by 4 publications

References 37 publications

Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives

Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives

The role of mesenchymal stem cells derived exosomes as a novel nanobiotechnology target in the diagnosis and treatment of cancer

Mesenchymal stem/stromal cells- a principal element for tumour microenvironment heterogeneity

Contact Info

Product

Resources

About